Morgan Stanley Upgrades Vertex Pharmaceuticals to Overweight on Kidney Pipeline Optimism

miércoles, 3 de diciembre de 2025, 1:51 pm ET1 min de lectura
MS--
VRTX--

Morgan Stanley upgraded Vertex Pharmaceuticals to overweight from equal-weight, citing optimism over its kidney condition pipeline. The bank boosted its price target to $516 from $438, representing a 19% upside based on the December 2 close.

Morgan Stanley Upgrades Vertex Pharmaceuticals to Overweight on Kidney Pipeline Optimism

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios